Pages that link to "Q24299848"

The following pages link to The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications (Q24299848):

Displaying 50 items.

• Furin, paired basic amino acid cleaving enzyme (Q581324) ‎ (← links)
• FURIN (Q14916427) ‎ (← links)
• Proprotein convertase subtilisin/kexin type 9 (Q21130010) ‎ (← links)
• Proprotein convertase subtilisin/kexin type 5 (Q21154237) ‎ (← links)
• Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation (Q24294486) ‎ (← links)
• Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH (Q24297165) ‎ (← links)
• Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly (Q24298534) ‎ (← links)
• The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2 (Q24301411) ‎ (← links)
• Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation (Q24303660) ‎ (← links)
• The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR (Q24303965) ‎ (← links)
• Self-association of human PCSK9 correlates with its LDLR-degrading activity (Q24306591) ‎ (← links)
• Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels (Q24313575) ‎ (← links)
• Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor (Q24321435) ‎ (← links)
• The PCSK9 decade (Q24615397) ‎ (← links)
• New developments in atherosclerosis: clinical potential of PCSK9 inhibition (Q26783407) ‎ (← links)
• Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9 (Q26786549) ‎ (← links)
• Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases (Q27009477) ‎ (← links)
• Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia (Q27013494) ‎ (← links)
• Molecular biology of PCSK9: its role in LDL metabolism (Q27488922) ‎ (← links)
• Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia (Q27644461) ‎ (← links)
• Molecular basis for LDL receptor recognition by PCSK9 (Q27649779) ‎ (← links)
• In vivo evidence that furin from hepatocytes inactivates PCSK9 (Q28504537) ‎ (← links)
• The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions (Q30541820) ‎ (← links)
• Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease (Q33599961) ‎ (← links)
• Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein (Q34227474) ‎ (← links)
• Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations (Q34306545) ‎ (← links)
• Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs (Q34430377) ‎ (← links)
• PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells (Q34433146) ‎ (← links)
• Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). (Q34458693) ‎ (← links)
• Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering (Q34536594) ‎ (← links)
• Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells (Q34560763) ‎ (← links)
• Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained (Q34649888) ‎ (← links)
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1) (Q34723257) ‎ (← links)
• Modulation of protease activated receptor 1 influences human metapneumovirus disease severity in a mouse model (Q34981539) ‎ (← links)
• PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9. (Q35262593) ‎ (← links)
• High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels (Q35911079) ‎ (← links)
• On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects (Q36035643) ‎ (← links)
• Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression (Q36078804) ‎ (← links)
• Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9. (Q36281706) ‎ (← links)
• Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels (Q36481769) ‎ (← links)
• Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line. (Q36574008) ‎ (← links)
• Autosomal dominant hypercholesterolemia: needs for early diagnosis and cascade screening in the tunisian population (Q36634114) ‎ (← links)
• Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation (Q36708550) ‎ (← links)
• The proprotein convertases are potential targets in the treatment of dyslipidemia (Q36757387) ‎ (← links)
• Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. (Q36812669) ‎ (← links)
• Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study (Q36854525) ‎ (← links)
• PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. (Q36862604) ‎ (← links)
• PCSK9 Association With Lipoprotein(a) (Q37037349) ‎ (← links)
• PCSK9: a convertase that coordinates LDL catabolism (Q37173223) ‎ (← links)
• Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice (Q37297854) ‎ (← links)